SCHEMBL3871472

SCHEMBL3871472

COC(=O)CCC(=O)c1ccc(CBr)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
MEN1 O00255 2/20 0.45
CYP1A2 P05177 1/20 0.45
ATM Q13315 1/20 0.45
MMP1 P03956 1/20 0.45
TSHR P16473 1/20 0.45
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
GSK3B P49841 1/20 0.43
RAB9A P51151 2/20 0.43
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3457642 0.84 KMT2A (0.47) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL9813840 0.84 THRA (0.60) L3MBTL1RAB9ATHRATHRBNPC1
SCHEMBL27498029 0.83 LOXL2 (0.61) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL7398 0.82 KMT2A (0.64) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL3844834 0.81 CYP4A11 (0.62) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL12315535 0.81 RAB9A (0.61) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL2305014 0.80 HSD17B3 (0.60) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL1483117 0.80 CYP4F2 (0.50) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL8535748 0.80 KMT2A (0.63) KMT2AALDH1A1LMNAMAPTHTT
Hydrochloric Acid SCHEMBL10866060 0.79 L3MBTL1 (0.47) KMT2AALDH1A1LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R KMT2A 1130/4885ALDH1A1 332/4885LMNA 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.